2025-01-24 18:41:33

Novo Nordisk (NVO.N) shares rose more than 8% in pre-market trading in the U.S. as clinical trials showed its weight loss drug Amycretin reduced body weight by 22%.
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
ASIA TECH WIRE

Grasp technology trends

Download